Emergent BioSolutions Inc. announced the execution of two contract options valued at $67.4 million to procure additional treatment courses of TEMBEXA (brincidofovir). This order is intended to sustain the U.S. government’s national preparedness posture against human smallpox.
TEMBEXA is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The contract options, CLIN0004A and CLIN0005A, fall under Emergent’s existing 10-year contract, which has a maximum potential value of $568 million.
The exercise of these options commits funding through 2027, ensuring a continued supply of TEMBEXA to address the threat of smallpox. This project is funded by the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA).
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.